Novo Nordisk's CagriSema Falls Short in Head to Head Trial vs Zepbound Bryce Platt, PharmD posted on the topic LinkedIn Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace Retatrutide vs Mounjaro (Tirzepatide): Which is Better? CagriTirz (Cagrilintide + Tirz) >99% Purity Obesity pharmacotherapy in older adults: a narrative review of evidence International Journal of Obesity